ホーム › 鎌状赤血球症 › イリノイ州 › Chicago
Chicago、ILにおける鎌状赤血球症の臨床試験
Chicagoとその周辺地域（約30マイル以内）の拠点で、鎌状赤血球症に関する18件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
被験者募集中第1相
- University of Illinois at Chicago College of Medicine, Chicago
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
被験者募集中第3相
- Uni of Illinois Hospital and HSC, Chicago
A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
被験者募集中第1相
- University of Illinois Hospital and Health Sciences System, Chicago
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
被験者募集中第3相
- Univer Of Illinois at Chicago, Chicago
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
被験者募集中第3相
- Childrens Hospital of Chicago, Chicago
- Univer Of Illinois at Chicago, Chicago
Tocilizumab for Acute Chest Syndrome
被験者募集中第2相
- University of Chicago, Chicago
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
被験者募集中第1/2相健康なボランティア歓迎
- Local Institution - 0034, Chicago
A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
被験者募集中第2/3相
- University of Illinois at Chicago Clinical Research Center, Chicago
- University of Illinois Hospital and Health Sciences System - Investigational Drug Services (IDS), Chicago
- University of Illinois Hospital and Health Sciences System, Chicago
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
被験者募集中観察研究
- Rush University Medical Center, Chicago
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
被験者募集中第2相
- University of Illinois at Chicago, Chicago
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
被験者募集中第3相
- University of Illinois-Chicago - College of Medicine- Site Number : 8400054, Chicago
Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
被験者募集中第2相
- University of Illinois at Chicago, Chicago
Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
被験者募集中観察研究
- Comer Children's Hospital (MRD-HCT), Chicago
Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
被験者募集中第2相
- University of Illinois Chicago, Sickle Cell Center, Chicago
Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease
被験者募集中
- University of Illinois at Chicago, Chicago
Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
被験者募集中第2相
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
被験者募集中
- Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago
Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
被験者募集中観察研究
- University of Illinois, Chicago
他の都市における鎌状赤血球症の試験
- Atlanta, GA22件の研究
- Washington, DC20件の研究
- Memphis, TN18件の研究
- Philadelphia, PA15件の研究
- Birmingham, AL14件の研究
- New York City, NY13件の研究
- St. Louis, MO12件の研究
- Durham, NC10件の研究
- Cincinnati, OH10件の研究
- Houston, TX10件の研究
- Boston, MA10件の研究
- Pittsburgh, PA9件の研究
Chicagoにおける他の研究
- 非小細胞肺癌61件の研究
- 乳がん58件の研究
- がん（全種類）51件の研究
- 転移性癌45件の研究
- 前立腺がん45件の研究
- 肥満症41件の研究
- 肺がん41件の研究
- 卵巣がん36件の研究
- 脳卒中34件の研究
- 大腸癌33件の研究
- 心不全31件の研究
- 過体重28件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。